Search Results - william+brennen

3 Results Sort By:
Mechanism-based 3rd Generation Quinoline-3-carboxamide HDAC4 Inhibitor for Metastatic Castration-resistant Prostate Cancer
Value Proposition:·        Metastatic castration-resistant prostate cancer (mCRPC) treatment that offers reduced side effects due to its mechanism of action (MoA)·        HDAC4 inhibition prevents the upregulation of stress survival pathways, which in turn may prevent metastases in mCRPC·        Similar anti-cancer agents must be dosed at lower concentrations...
Published: 7/5/2024   |   Inventor(s): John Isaacs, William Brennen, Emmanuel Akinboye
Keywords(s):  
Category(s): Clinical and Disease Specializations > Oncology > Prostate Cancer, Clinical and Disease Specializations > Oncology
Novel prodrug strategy to improve clinical use of cancer drugs
Unmet Need / Invention Novelty: Clinical translation of various has been limited due to poor solubility and toxicity for repurposed anti-cancer applications. There exists an unmet need to develop new strategies to overcome these limitations. Technical Details: Researchers at Johns Hopkins have developed a novel prodrug strategy to improve solubility...
Published: 7/5/2024   |   Inventor(s): William Brennen, John Isaacs, Samuel Denmeade, Emmanuel Akinboye
Keywords(s):  
Category(s): Clinical and Disease Specializations > Oncology
Human Serum Albumin-PSA proaerolysin Prodrug
UNMET NEEDThe current standards of care for prostate cancer (Pca) include hormonal therapy, radiation therapy, surgery, chemotherapy, and combinational therapy. However, these treatments often have side effects that affect the quality of life of the Pca patients. Hence, there is an urgent need for developing better target-based therapies. This technology...
Published: 7/4/2024   |   Inventor(s): John Isaacs, Samuel Denmeade, William Brennen
Keywords(s): Biologics, Cancers, Disease Indication, Drug Delivery Vehicle, Peptides/Prodrugs, Prostate Cancer, Protein, Therapeutic Matter, Therapeutic Substance, Therapeutics
Category(s): Clinical and Disease Specializations, Clinical and Disease Specializations > Men's Health, Technology Classifications > Therapeutic Modalities > Biologics, Technology Classifications > Therapeutic Modalities > Proteins, Technology Classifications > Therapeutic Modalities > Peptides, Technology Classifications > Therapeutic Modalities > Therapeutic Delivery Platforms, Clinical and Disease Specializations > Oncology, Technology Classifications > Therapeutic Modalities, Clinical and Disease Specializations > Oncology > Prostate Cancer
2017 - 2022 © Johns Hopkins Technology Ventures. All Rights Reserved. Powered by Inteum